Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia

Blood

Volumn 111, Issue 9, 2008, Pages 4797-4808

  Tomasson, Michael H ^a,d   Xiang, Zhifu ^a   Walgren, Richard ^a   Zhao, Yu ^a   Kasai, Yumi ^a   Miner, Tracie ^a   Ries, Rhonda E ^a   Lubman, Olga ^a   Fremont, Daved H ^a   McLellan, Michael D ^a   Payton, Jacqueline E ^a   Westervelt, Peter ^a   DiPersio, John F ^a   Link, Daniel C ^a   Walter, Matthew J ^a   Graubert, Timothy A ^a   Watson, Mark ^a   Baty, Jack ^b   Heath, Sharon ^a   Shannon, William D ^a,b   Nagarajan, Rakesh ^a   Bloomfield, Clara D ^c   Mardis, Elaine R ^a   Wilson, Richard K ^a   Ley, Timothy J ^a   more..

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b USA   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d Division of Oncology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLT3 LIGAND; GENOMIC DNA; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE 3; PROTEIN DDR1; PROTEIN KINASE FYN; PROTEIN KINASE TYK2; PROTEIN LTK; PROTEIN NTRK1; PROTEIN TYROSINE KINASE; STEM CELL FACTOR; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; FEMALE; GENE FREQUENCY; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN EXPRESSION; SEQUENCE ANALYSIS; SOMATIC MUTATION; GENETICS; MUTATION;

DNA MUTATIONAL ANALYSIS; GERM-LINE MUTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MUTATION; PROTEIN-TYROSINE KINASES;

EID: 47149087181     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2007-09-113027     Document Type: Article

References (58)

1. Slamon DJ, Leyland-Jones B. Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 tor metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-792.
2. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031-1037.
3. Gilliland DG, Griffin JD. Role of FLT3 in leukemia. Curr Opin Hematol. 2002;9:274-281.
4. Ridge SA, Worwood M, Oscier D, Jacobs A, Padua RA. FMS mutations in myelodysplastic, leukemic, and normal subjects. Proc Natl Acad Sci USA. 1990;87:1377-1380.
5. Wang YY, Zhou GB, Yin T, et al. AMLIETO and C-KIT mutation/overexpression in t(8;21) leukemia: implication in stepwise leukemogenesis and response to Gleevec. Proc Natl Acad Sci USA. 2005:102:1104-1109.
6. GolubTR, Barker GF, Lovett M, Gilliland DG. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell. 1994;77:307-316.
7. Eguchi M, Eguchi-lshimae M, Tojo A, et al. Fusion of ETV6 to neurotrophin-3 receptor TRKG in acute myeloid leukemia with t(12;15)(p13;q25). Blood. 1999;93:1355-1363.
8. Xiao S, Nalabolu SR, Aster JC, et al. FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoma syndrome. Nat Genet. 1998;18:84-87.
9. Rowley J D. Chromosomal patterns in myelocytic leukemia. N Engl J Med. 1973;289:220-221.
10. LacroniqueV, Boureux A, Valle VD, et al. ATELJAK2 fusion protein with constitutive kinase activity in human leukemia. Science. 1997;278:1309-1312.
11. Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science. 1994;263:1281-1284.
12. Cazzaniga G, Tosi S, Aloisi A, et al. The tyrosine kinase abl-related gene ARG is fused to ETV6 in an AML-M4Eo patient with a t(1;12) (q25;p13): molecular cloning of both reciprocal transcripts. Blood. 1999;94:4370-4373.
13. Nakao M, Yokota S, IwaiT, et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia. 1996;10:1911-1918.
14. Beghini A, Peterlongo P, Ripamonti CB, et al. Ckit mutations in core binding factor leukemias. Blood. 2000;95:726-727.
15. Kelly LM, Kutok JL, Williams IR, et al. PML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse model. Proc Natl Acad Sci U S A. 2002;99:8283-8288.
16. Dash AB, Williams IR, Kutok JL, et al. A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9. Proc Natl Acad Sci USA. 2002;99:7622-7627.
17. Grisolano JL, O'Neal J, Cain J, Tomasson MH. An activated receptor tyrosine kinase, TEL/PDGFbetaR, cooperates with AML1/ETO to induce acute myeloid leukemia in mice. Proc Natl Acad Sci U S A. 2003;100:9506-9511.
18. Wolfler A, Erkeland SJ, Bodner C, et al. Afunctional single-nucleotide polymorphism of the GCSF receptor gene predisposes individuals to high-risk myelodysplastic syndrome. Blood. 2005; 105:3731-3736.
19. SchnittgerS, Kohl TM, Leopold N, et al. D324N single-nucleotide polymorphism in the FLT3 gene is associated with higher risk of myeloid leukemias. Genes Chromosomes Cancer. 2006;45:332-337.
20. Link DC, Kunter G, Kasai Y, et al. Distinct patterns of mutations occurring in de novo AML versus AM L arising in the setting of severe congenital neutropenia. Blood 2007;110:1648-1655.
21. Ley TJ, Minx PJ, Walter MJ. et al. A pilot study of high-throughput, sequence-based mutational profiling of primary human acute myeloid leukemia cell genomes. Proc Natl Acad Sci USA. 2003; 100:14275-14280.
22. Yuan W. Payton JE, Holt MS, et al. Commonly dysregulated genes in murine APL cells. Blood. 2007;109:961-970.
23. Ambrosius WT, Lange EM, Langefeld CD. Power for genetic association studies with random allele frequencies and genotype distributions. Am J Hum Genet. 2004;74:683-693.
24. Reuther GW, Lambert QT, Caligiuri MA, Der CJ. Identification and characterization of an activating TrkA deletion mutation in acute myeloid leukemia. Mol Cell Biol. 2000;20:8655-8666.
25. Xiang Z. Zhao Y, Mitaksov V. et al. Identification of somatic JAK1 mutations in patients with acute myeloid leukemia. Blood. 2008;111 4809-4812.
26. Kelley LA, MacCallum RM, Sternberg MJ. Enhanced genome annotation using structural profiles in the program 3D-PSSM. J Mol Biol. 2000; 299:499-520.
27. Schindler T, Sicheri F, Pico A, Gazit A, Levitzki A, Kuriyan J. Crystal structure of Hck in complex with a Src family-selective tyrosine kinase inhibitor. Mol Cell. 1999;3:639-648.
28. Greenman C, Stephens P, Smith R, et al. Patterns of somatic mutation in human cancer genomes. Nature. 2007;446:153-158.
29. Bardelli A, Parsons DW, Silliman N, et al. Mutational analysis of the tyrosine kinome in colorectal cancers. Science. 2003;300:949.
30. Sjoblom T, Jones S, Wood LD, et al. The consensus coding sequences of human breast and colorectal cancers. Science. 2006;314:268-274.
31. Stephens P, Edkins S, Davies H, et al. A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer. Nat Genet. 2005;37:590-592.
32. Mulloy JC, Jankovic V, Wunderlich M, et al. AMLIETO fusion protein up-regulates TRKA mRNA expression in human CD34 + cells, allowing nerve growth factor-induced expansion. Proc Natl Acad Sci USA. 2005;102:4016-4021.
33. Chiaretti S, Li X, Gentleman R, et al. Gene expression profiles of B-lineage adult acute lymphocytic leukemia reveal genetic patterns that identify lineage derivation and distinct mechanisms of transformation. Clin Cancer Res. 2005;11:7209-7219.
34. Walters DK, Mercher T, Gu TL, et al. Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cell. 2006;10:65-75.
35. Sigurdsson S, Nordmark G, Goring HH, et al. Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus. Am J Hum Genet. 2005;76:528-537.
36. Graham DS, Akil M, Vyse TJ. Association of polymorphisms across the tyrosine kinase gene, TYK2 in UK SLE families. Rheumatology (Oxf). 2007;46:927-930.
37. Kaminker JS, Zhang Y Waugh A, et al. Distinguishing cancer-associated missense mutations from common polymorphisms. Cancer Res. 2007;67:465-473.
38. Song WJ, Sullivan MG, Legare RD, et al. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet. 1999;23:166-175.
39. Smith ML, Cavenagh JD, Lister TA, Fitzgibbon J. Mutation of CEBPA in familial acute myeloid leukemia. N Engl J Med. 2004;351:2403-2407.
40. Knoche E, McLeod HL, Graubert TA. Pharmacogenetics of alkylator-associated acute myeloid leukemia. Pharmacogenomics. 2006;7:719-729.
41. Strauss BS. Hypermutability in carcinogenesis. Genetics. 1998;148:1619-1626.
42. Wang TL, Rago C, Silliman N, et al. Prevalence of somatic alterations in the colorectal cancer cell genome. Proc Natl Acad Sci USA. 2002;99:3076-3080.
43. Paschka P, Marcucci G, Ruppert AS, et al. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol. 2006;24:3904-3911.
44. Cairoli R, BeghiniA, Grillo G, et al. Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study. Blood. 2006;107:3463-3468.
45. Schnittger S, Kohl TM. Haferlach T, et al. KITD816 mutations in AMLIETO-positive AML are associated with impaired event-free and overall survival. Blood. 2006;107:1791-1799.
46. Nanri T. Matsuno N, KawakitaT, et al. Mutations in the receptor tyrosine kinase pathway are associated with clinical outcome in patients with acute myeloblastic leukemia harboring t(8;21)(q22; q22). Leukemia. 2005;19:1361-1366.
47. Schnittger S, Schoch C, Dugas M, et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker tor the detection of minimal residual disease. Blood. 2002; 100:59-66.
48. Thiede C, Steudel C, Mohr B, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood. 2002;99:4326-4335.
49. Ignatoski KM, LapointeAJ, Radany EH, Ethier SP. erbB-2 overexpression in human mammary epithelial cells confers growth factor independence. Endocrinology. 1999:140:3615-3622.
50. Verbeek BS, Adriaansen-Slot SS, Vroom TM, Beckers T, Rijksen G. Overexpression of EGFR and c-erbB2 causes enhanced cell migration in human breast cancer cells and NIH3T3 fibroblasts. FEBS Lett. 1998;425:145-150.
51. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387-397.
52. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054-1061.
53. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779-1790.
54. James C, Ugo V, Le Gouedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005; 434:1144-1148.
55. Whitman SP, Archer KJ, Feng L, et al. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. Cancer Res. 2001;61:7233-7239.
56. Bowen DT, Frew ME, Hills R, et al. RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years. Blood. 2005;106:2113-2119.
57. Bacher U, Haferlach T, Kern W, Haferlach C, Schnittger S. A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia. Haematologica. 2007;92:744-752.
58. Kimchi-Sarfaty C, Oh JM, Kim IW, et al. A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science. 2007;315:525-528.